These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 8150784)

  • 21. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors.
    Tolgay Ocal I; Dolled-Filhart M; D'Aquila TG; Camp RL; Rimm DL
    Cancer; 2003 Apr; 97(8):1841-8. PubMed ID: 12673709
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A multimarker model to predict outcome in tamoxifen-treated breast cancer patients.
    Linke SP; Bremer TM; Herold CD; Sauter G; Diamond C
    Clin Cancer Res; 2006 Feb; 12(4):1175-83. PubMed ID: 16489071
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular prognostic markers in pancreatic cancer.
    Ghaneh P; Kawesha A; Evans JD; Neoptolemos JP
    J Hepatobiliary Pancreat Surg; 2002; 9(1):1-11. PubMed ID: 12021893
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Node negative breast carcinoma: hyperprolactinemia and/or overexpression of p53 as an independent predictor of poor prognosis compared to newer and established prognosticators.
    Patel DD; Bhatavdekar JM; Chikhlikar PR; Ghosh N; Suthar TP; Shah NG; Mehta RH; Balar DB
    J Surg Oncol; 1996 Jun; 62(2):86-92. PubMed ID: 8649046
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Standardization of immunobioassays as surrogate endpoints.
    Masood S
    J Cell Biochem Suppl; 1994; 19():28-35. PubMed ID: 7823602
    [TBL] [Abstract][Full Text] [Related]  

  • 26. C-erbB-2 expression is a better predictor for survival than galectin-3 or p53 in early-stage breast cancer.
    Logullo AF; Lopes AB; Nonogaki S; Soares FA; Netto MM; Nishimoto IN; Brentani MM
    Oncol Rep; 2007 Jul; 18(1):121-6. PubMed ID: 17549356
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modulation of molecular marker expression by induction chemotherapy in locally advanced breast cancer: correlation with the response to therapy and the expression of MDR1 and LRP.
    Schneider J; Lucas R; Sánchez J; Ruibal A; Tejerina A; Martín M
    Anticancer Res; 2000; 20(6B):4373-7. PubMed ID: 11205274
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor.
    Chang J; Clark GM; Allred DC; Mohsin S; Chamness G; Elledge RM
    Cancer; 2003 Feb; 97(3):545-53. PubMed ID: 12548595
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cyclin E as a prognostic and predictive marker in breast cancer.
    Hunt KK; Keyomarsi K
    Semin Cancer Biol; 2005 Aug; 15(4):319-26. PubMed ID: 16043362
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Flow cytometry: a new approach for the molecular profiling of breast cancer.
    Lostumbo A; Mehta D; Setty S; Nunez R
    Exp Mol Pathol; 2006 Feb; 80(1):46-53. PubMed ID: 16271361
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Recent prognostic factors for breast cancer].
    Ikeda T
    Gan To Kagaku Ryoho; 1997 Apr; 24(6):635-43. PubMed ID: 9126298
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognosis-related histomorphological and immunohistochemical markers in central nervous system tumors of childhood and adolescence.
    Rickert CH; Paulus W
    Acta Neuropathol; 2005 Jan; 109(1):69-92. PubMed ID: 15647946
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Implications of the new biology for therapy in breast cancer.
    Sledge GW
    Semin Oncol; 1996 Feb; 23(1 Suppl 2):76-81. PubMed ID: 8614850
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The molecular pathology of human breast cancer.
    Walker RA; Varley JM
    Cancer Surv; 1993; 16():31-57. PubMed ID: 8348538
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Apoptosis and angiogenesis: two promising tumor markers in breast cancer (review).
    Wu J
    Anticancer Res; 1996; 16(4B):2233-9. PubMed ID: 8694549
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oncogenes and oncoproteins as tumor markers.
    Pillai R
    Eur J Surg Oncol; 1992 Oct; 18(5):417-24. PubMed ID: 1426290
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Future prospects for the use of tumor markers].
    Grunicke H
    Wien Klin Wochenschr; 1989 Jul; 101(14):472-5. PubMed ID: 2672607
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Breast cancer biomarkers and molecular medicine.
    Ross JS; Linette GP; Stec J; Clark E; Ayers M; Leschly N; Symmans WF; Hortobagyi GN; Pusztai L
    Expert Rev Mol Diagn; 2003 Sep; 3(5):573-85. PubMed ID: 14510178
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oncogenes, tumour suppressor genes and growth factors in breast cancer: novel targets for diagnosis, prognosis and therapy.
    Callahan R; Salomon DS
    Cancer Surv; 1993; 18():35-56. PubMed ID: 8012999
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Growth factors and their receptors.
    Tripathy D; Benz C
    Hematol Oncol Clin North Am; 1994 Feb; 8(1):29-50. PubMed ID: 8150783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.